1 / 53

Economics 105: Statistics

Economics 105: Statistics. Any questions? No GH due Friday. For next couple classes, please r ead first 4 sections of Chapter 13 and Freakonomics , Chapter 5 (copy is in P:economicsEco 105 (Statistics) Foley freakonomics Ch_5.pdf). Brief Introduction to Research Design.

nuru
Download Presentation

Economics 105: Statistics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Economics 105: Statistics Any questions? No GH due Friday. For next couple classes, please read first 4 sections of Chapter 13 and Freakonomics, Chapter 5 (copy is in P:\economics\Eco 105 (Statistics) Foley\freakonomics Ch_5.pdf)

  2. Brief Introduction to Research Design Design Notation Internal Validity Experimental Design

  3. Design Notation • Observations or measures are indicated with an “O” • Treatments or programs with an “X” • Groups are shown by the number of rows • Assignment to group is by “R,N,C” • Random assignment to groups • Nonequivalent assignment to groups • Cutoff assignment to groups • Time

  4. There are two lines, one for each group. Vertical alignment of Os shows that pretest and posttest are measured at same time. X is the treatment. Subscripts indicate subsets of measures. Os indicate different waves of measurement. Design Notation Example R O1,2 X O1,2 R O1,2 O1,2 R indicates the groups are randomly assigned.

  5. Yes Randomized (true experiment) No Nonexperiment Types of Designs Random assignment? No Control group or multiple measures? Yes Quasi-experiment

  6. Non-Experimental Designs X O Post-test only (case study) O X O Single-group, pre-test, post-test X O O Two-group, post-test only (static group comparison)

  7. Experimental Designs • Pretest-Posttest Randomized Experiment Design • If continuous measures, use t-test • If categorical outcome, use chi-squared test • Posttest only Randomized Experiment Design • Less common due to lack of pretest • Probabilistic equivalence between groups

  8. Experimental Designs Solomon Four-Group Design • Advantages • Information is available on the effect of treatment (independent variable), the effect of pretesting alone, possible interaction of pretesting & treatment, and the effectiveness of randomization • Disadvantages • Costly and more complex to implement

  9. Establishing Cause and Effect Single-Group Threats Multiple-Group Threats “Social” Interaction Threats Internal Validity • Internal validity is the approximate truth about inferences regarding cause-effect relationships. • “Internal” means internal to the study, not “external”, that is, not talking about generalizing the results yet.

  10. Threats to Internal Validity History Maturation Testing Instrumentation Mortality Regression to the mean Selection Selection-history Selection- maturation Selection- testing Selection- instrumentation Selection- mortality* Selection- regression Diffusion or imitation* Compensatory equalization* Compensatory rivalry* Resentful demoralization* R X O R O Single-Group Multiple-Group Social Interaction

  11. Single-Group Threatsto Internal Validity

  12. Administer program Measure outcomes X O Administer program Measure outcomes X O What is a “single-group” threat? Two designs: Post-test only a single group Measure baseline O

  13. Example • Diabetes educational program for newly diagnosed adolescents in a clinic • Pre-post, single group design • Measures (O) are paper-pencil, standardized tests of diabetes knowledge (e.g. disease characteristics, management strategies)

  14. Pretest Program Posttest O X O History Threat • Any other event that occurs between pretest and posttest • For example, adolescents learn about diabetes by watching The Health Channel

  15. Pretest Program Posttest O X O Maturation Threat • Normal growth between pretest and posttest. • They would have learned these concepts anyway, even without program.

  16. Pretest Program Posttest O X O Testing Threat • The effect on the posttest of taking the pretest • May have “primed” the kids or they may have learned from the test, not the program • Can only occur in a pre-post design

  17. Pretest Program Posttest O X O Instrumentation Threat • Any change in the test from pretest and posttest • So outcome changes could be due to different forms of the test, not due to program • May do this to control for “testing” threat, but may introduce “instrumentation” threat

  18. Pretest Program Posttest O X O Mortality Threat • Nonrandom dropout between pretest and posttest • For example, kids “challenged” out of program by parents or clinicians • Attrition

  19. Pretest Program Posttest O X O Regression Threat • Group is a nonrandom subgroup of population. • For example, mostly low literacy kids will appear to improve because of regression to the mean. • Example: height

  20. Regression to the Mean pre-test scores ~ N When you select a sample from the low end of a distribution ... Selected group’s mean Overall mean the group will do better on a subsequent measure. post-test scores ~ N & assuming no effect of treatment pgm The group mean on the first measure appears to “regress toward the mean” of the population. Overall mean Regression to the mean

  21. Regression to the Mean

  22. Regression to the Mean • How to Reduce the effects of RTM (Barnett, et al., International Journal of Epidemiology, 2005) • When designing the study, randomly assign subjects to treatment and control (placebo) groups. Then effects of RTM on responses should be same across groups. • Select subjects based on multiple measurements • RTM increases with larger variance (see graphs) so subjects can be selected using the average of 2 or more baseline measurements.

  23. Multiple-Group Threats to Internal Validity

  24. The Central Issue • When you move from single to multiple group research the big concern is whether the groups are comparable. • Usually this has to do with how you assign units (e.g., persons) to the groups (or select them into groups). • We call this issue selection or selection bias.

  25. O X O O O The Multiple Group Case Alternative explanations Measure baseline Administer program Measure outcomes Do not administer program Measure baseline Measure outcomes Alternative explanations

  26. Example • Diabetes education for adolescents • Pre-post comparison group design • Measures (O) are standardized tests of diabetes knowledge

  27. O X O O O Selection-History Threat • Any other event that occurs between pretest and posttest that the groups experience differently. • For example, kids in one group pick up more diabetes concepts because they watch a special show on Oprah related to diabetes.

  28. O X O O O Selection-Maturation Threat • Differential rates of normal growth between pretest and posttest for the groups. • They are learning at different rates, even without program.

  29. O X O O O Selection-Testing Threat • Differential effect on the posttest of taking the pretest. • The test may have “primed” the kids differently in each group or they may have learned differentially from the test, not the program.

  30. O X O O O Selection-Instrumentation Threat • Any differential change in the test used for each group from pretest and posttest • For example, change due to different forms of test being given differentially to each group, not due to program

  31. O X O O O Selection-Mortality Threat • Differential nonrandom dropout between pretest and posttest. • For example, kids drop out of the study at different rates for each group. • Differential attrition

  32. O X O O O Selection-Regression Threat • Different rates of regression to the mean because groups differ in extremity. • For example, program kids are disproportionately lower scorers and consequently have greater regression to the mean.

  33. “Social Interaction” Threats to Internal Validity

  34. What Are “Social” Threats? • All are related to social pressures in the research context, which can lead to posttest differences that are not directly caused by the treatment itself. • Most of these can be minimized by isolating the two groups from each other, but this leads to other problems (for example, hard to randomly assign and then isolate, or may reduce generalizability).

  35. Diffusion or Imitation of Treatment • Controls might learn about the treatment from treated people (for example, kids in the diabetes educational group and control group share the same hospital cafeteria and talk with one another).

  36. Compensatory Equalization of Treatment • Administrators give a compensating treatment to controls. • Researchers feel badly and give control group kids a video to watch pertaining to diabetes. Contaminates the study! =

  37. Compensatory Rivalry • Controls compete to keep up with treatment group.

  38. Resentful Demoralization • Controls "give up" or get discouraged • Likely to exaggerate the posttest differences, making your program look more effective than it really is

  39. What is a Clinical Trial? • “A prospective study comparing the effect and value of intervention(s) against a control in human beings.” • Prospective means “over time”; vs. retrospective • It is attempting to change the natural course of a disease • It is NOT a study of people who are on drug X versus people who are not • http://www.clinicaltrials.gov/info/resources

  40. Model of Two-Group Randomized Clinical Trial

  41. What are the characteristics of a Clinical Trial? • Begins with a primary research question, and the trial design flows from this question (constrained by practicalities) • Everything must be exhaustively defined in advance (to prevent accusations of fishing for a positive finding) • The hypothesis (“-es”) • Population to be studied • inclusion criteria • exclusion criteria • contraindications to therapy • indications to therapy • Treatment strategy (treatment, exact dosage, dosage schedule, etc) • The outcome(s)

  42. Beta-Blocker Heart Attack Trial (BHAT) • Published in Journal of the American Medical Association • JAMA 1982; 247: 1701 - 1714 • JAMA 1983; 250: 2814 – 2819 • Up until about 25 years ago, the treatment of myocardial infarction consisted of bed rest, alleviation of symptomatic pain, possible administration of early antiarrhythmics • But a third of people who have a heart attack die from it ‘suddenly’ • In 1976, NIH sponsored a conference to discuss potential agents to be used in either a primary or secondary prevention setting to reduce sudden death, for which there was no treatment. • The conference made an official recommendation to do a clinical trial.

  43. Beta-Blocker Heart Attack Trial (BHAT) • Primary Research Question • To test in a multicenter, randomized, double-blind, placebo, controlled trial, whether the daily administration of propranolol to patients who had had at least one documented MI would results in a significant reduction in all-cause mortality during 2 to 4 years of follow-up (expected mean follow-up = 36 months).

  44. Beta-Blocker Heart Attack Trial (BHAT) • Inclusion criteria • Men/Women • Aged 30 to 69 yrs • Documented (defined) MI within 5 to 21 days of randomization • Exclusion criteria • Contraindication to propranolol (e.g., asthma, severe bradycardia) • Likely to be prescribed propranolol (e.g., for severe angina) • Unlikely to be a compliant participant • Likely to die of noncardiac cause (e.g., cancer) • What do these do to generalizability?

  45. BHAT Design and Conduct 1916 Patients - Propranolol 138 Deaths 188 1921 Patients - Placebo Deaths Screened Randomized 16,400 3,837 Patients Treat and Participants Collect Follow-up Data Time M ean 2 yrs (trial stopped early) Follow-up Time

  46. Beta-Blocker Heart Attack Trial (BHAT) • Results • BHAT (and similar trials) demonstrated great benefitin reducing all-cause mortality and cardiac-specific mortality (including sudden death)in three-quarters of Post-MI Patients (1/4 had contraindication to propranolol) • Relevance today? • Beta-blockers still should be given post-MI • What happened after BHAT is illustrative of what often happens a clinical trial result is published • Results reported in 1981 (short report in JAMA) • In 1987, only 36% of post-MI patients on a beta-blocker • In 1989, 40% • In 1992, 63% • In 1993, only 33% of post-MI women

  47. Example: Job Corps • What is Job Corps? http://jobcorps.doleta.gov/ • January 5, 2006 Thursday Late Edition – Final SECTION: Section C; Column 1; Business/Financial Desk; ECONOMIC SCENE; Pg. 3HEADLINE: New (and Sometimes Conflicting) Data on the Value to Society of the Job CorpsBYLINE: By Alan B. Krueger. Alan B. Krueger is the Bendheim professor of economics and public affairs at Princeton University. His Web site is www.krueger.princeton.edu. He delivered the 2005 Cornelson Lecture in the Department of Economics here at Davidson (that’s the big econ lecture each year).

  48. Example: Job Corps • Quotations from “New (and Sometimes Conflicting) Data on the Value to Society of the Job Corps” by Alan B. Krueger. • Since 1993, Mathematica Policy Research Inc. has evaluated the performance of the Job Corps for the Department of Labor. • Its evaluation is based on one of the most rigorous research designs ever used for a government program. From late 1994 to December 1995, some 9,409 applicants to the Job Corps were randomly selected to be admitted to the program and another 6,000 were randomly selected for a control group that was excluded from the Job Corps. • Those admitted to the program had a lower crime rate, higher literacy scores and higher earnings than the control group.

  49. RCT for Credit Card Offers Source: Agarwal, et al. (2010), Journal of Money, Credit & Banking, 42 (4)

More Related